This is the authors' abstract. We don't add key points for this paper.
Transcriptomic response biomarkers for immune-checkpoint blockade remain poorly defined across cancers. We developed the two-gene Myeloid-Adaptive Response to Atezolizumab (MARTA) score, integrating CXCL13 and CXCL8 expression. MARTA was developed in 81 atezolizumab-treated patients in IMmotion150, evaluated across treatment groups, and independently assessed in IMvigor210. In IMmotion150, higher MARTA was associated with higher objective response rate (ORR) with atezolizumab alone (odds ratio [OR], 3.20; 95% confidence interval [CI], 1.42–7.19) and atezolizumab plus bevacizumab (OR, 2.61; 95% CI, 1.43–4.76), but not with sunitinib. Higher MARTA was associated with longer progression-free survival (PFS) in both atezolizumab-containing groups (hazard ratio [HR], 0.60 and 0.65), but not with sunitinib (interaction p = 0.01). In IMvigor210, higher MARTA was associated with higher ORR (OR per 1-standard-deviation increase, 1.38; 95% CI, 1.05–1.81) and longer overall survival (OS) (HR, 0.76; 95% CI, 0.67–0.86). The OS association remained after multivariate adjustment (HR, 0.81; 95% CI, 0.69–0.95). Discrimination for ORR and OS, assessed by the area under the curve (AUC) and C-index, respectively, was modest for MARTA, tGE8, and the IFN-γ signature. These findings support further evaluation of MARTA, while prospective validation and cross-platform analytical reproducibility remain necessary before clinical application.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Mario Uccello (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: